Melbourne – September 21, 2026 -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) has signed a strategic agreement to merge with ITM Isotope Technologies Munich SE in a deal valuing ITM at US$1.65 billion upfront on a cash-free, debt-free basis, with up to US$700 million in additional contingent consideration tied to regulatory and sales milestones.

Shanghai – September 20, 2026 -- Abbisko Therapeutics Co., Ltd. (HKEX: 02256.HK) reported that its oral FGFR2/3 inhibitor lavengratinib achieved a mean increase of 2.4 cm/year in annualized height velocity among children with achondroplasia in the lowest-dose cohort of a Phase II trial, with a 100% responder rate.

Shanghai – September 20, 2026 -- Antengene Corporation Limited (SEHK: 6996.HK) has dosed the first patient in China in its pivotal Phase III CLINCH-3 study evaluating ATG-022, a CLDN18.2 antibody-drug conjugate, as monotherapy for CLDN18.2-positive advanced gastric or gastroesophageal junction adenocarcinoma.

Singapore – September 20, 2026 -- Specialised Therapeutics (ST) has expanded its partnership with Incyte Biosciences International to commercialise, distribute, and register ruxolitinib cream, marketed as Opzelura, in Australia.

Shanghai – – September 20, 2026 -- Ten biotech startup teams have been selected as finalists for the inaugural S2S China Symposium, narrowed from roughly 20 semifinalists who competed to pitch global venture investors at Westlake University on October 15.

New York and Suzhou, China – September 20, 2026 -- Accro Bioscience Inc. has dosed its first patient in a Phase IIb trial testing AC-101, a selective RIPK2 inhibitor, in patients with moderate-to-severe ulcerative colitis (UC).

Rochester, Mich. – September 20, 2026 -- Par Health is voluntarily recalling two lots of Dexmedetomidine HCl in 0.9% Sodium Chloride Injection 400 mcg/100 mL (4 mcg/mL) at the hospital level after detecting particulate matter identified as cellulose or stopper material.

Indianapolis – September 20, 2026 -- The U.S. Food and Drug Administration has granted full approval to Eli Lilly and Company's (NYSE: LLY) Inluriyo (imlunestrant) in combination with Verzenio (abemaciclib) for adults with estrogen receptor-positive (ER+), HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer whose disease progressed after at least one line of endocrine therapy.

Huntersville, N.C. – September 20, 2026 -- BioCytics, Inc. has engaged Eremid Genomic Services to perform single cell transcriptomic and TCR sequencing analysis on immune cells central to its autologous cancer cell therapy program.

Seoul – September 20, 2026 -- NAVER D2SF, the in-house corporate venture arm of NAVER, has joined a $10 million Series A2 bridge round for Silicon Valley-based precision medicine company ImpriMed, backing its push toward U.S. regulatory clearance and Asian market expansion.